Study Explains Why Patients with Cancer Spread to the Liver Have Worse Outcomes

The liver siphons critical immune cells to render immunotherapy ineffective; radiation to the liver may block this process.

9:31 AM

Author | Nicole Fawcett

liver cancer red and orange in a blue body virtual drawing
Getty Images

Michael Green, M.D., Ph.D., noticed that when his patients had cancer that spread to the liver, they fared poorly – more so than when cancer spread to other parts of the body. Not only that, but transformative immunotherapy treatments had little impact for these patient.

Uncovering the reason and a possible solution, a new study, published in Nature Medicine, finds that tumors in the liver siphon off critical immune cells, rendering immunotherapy ineffective. But coupling immunotherapy with radiotherapy to the liver in mice restored the immune cell function and led to better outcomes.

"Patients with liver metastases receive little benefit from immunotherapy, a treatment that has been a game-changer for many cancers. Our research suggests that we can reverse this resistance using radiation therapy. This has potential to make a real difference in outcomes for these patients," says Green, assistant professor of radiation oncology at Michigan Medicine and corresponding author on the paper.

A multidisciplinary team from the University of Michigan Rogel Cancer Center looked at data from 718 patients who had received immunotherapy at the center. Patients had a variety of cancer types, including non-small cell lung cancer, melanoma, urothelial cancer and renal cell cancer, which had spread to different organs, including the liver and lungs.

Repeatedly, those with liver metastases had worse responses to immunotherapy. The issue was not just in the liver either: these patients had more cancer throughout their bodies, compared to similar patients whose cancer had spread but not to the liver.

"The liver is initiating a systemic immunosuppressive mechanism. The mechanism happens in the liver, but we see the systemic impact throughout the body," says corresponding study author Weiping Zou, M.D., Ph.D., Charles B. de Nancrede Professor of Surgery, Pathology, Immunology and Biology at the University of Michigan.

The liver is one of the most common sites to which cancer metastasizes. It's known to interfere with immune response in autoimmune diseases, viral infections and organ transplants by suppressing certain critical immune cells.

This was playing out in metastatic cancer as oncologists observed a lack of immune response. Green notes that patients with liver metastases who received chemotherapy or targeted therapies did not have worse outcomes compared to those with other types of metastases. "It's unique to immunotherapy," he says.

Looking within the microenvironment of the liver metastases, researchers saw that the tumors were siphoning off the T cells – immune cells that should have been working to attack the cancer. Not only were the T cells being eliminated in the liver, but this was also creating an immune desert throughout the body. As a result, the immune system could not be activated to fight tumors at any sites.

Using mice with liver metastases, researchers delivered radiation therapy directly to the tumors in the liver. This stopped T cell death. With the T cells restored, an immune checkpoint inhibitor was then able to activate the immune system to eliminate the cancer throughout the body, on par with results seen in non-liver metastases.

"It's always a challenge to identify a novel mechanism of immune suppression and find a way to address it. With these promising results, we are now looking to open clinical trials in this space to better understand the mechanisms at play in human tumors," Green says.

Clinical trials are currently being developed but are not yet available. Learn about clinical trials open at the Rogel Cancer Center.

Additional authors are Jiali Yu, Shasha Li, Yilun Sun, Sara Journey, Jae Eu Choi, Syed Monem Rizvi, Angel Qin, Jessica F. Waninger, Xueting Lang, Zoey Chopra, Issam El Naqa, Jiajia Zhou, Yingjie Bian, Long Jiang, Alangoya Tezel, Jeremy Skvarce, Rohan K. Achar, Merna Sitto, Benjamin Rosen, Fengyun Su, Sathiya Narayanan, Xuhong Cao, Shuang Wei, Wojciech Szeliga, Linda Vatan, Charles Mayo, Meredith Morgan, Caitlin Schonewolf, Kyle Cuneo, Ilona Kryczek, Vincent Ma, Leslie Fecher, Christopher Lao, Theodore S. Lawrence, Nithya Ramnath, Fei Wen, Arul Chinnaiyan, Marcin Cieslik and Ajjai Alva.

Funding was from National Cancer Institute grants CA248430, CA217648, CA123088, CA099985, CA193136, CA152470, 1UM1HG006508, U01CA216440 and P30CA46592.

Paper cited: "Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination," Nature Medicine. DOI: 10.1038/s41591-020-1131-x


More Articles About: Lab Report Cancer Research Liver Cancer Rogel Cancer Center Health Care Quality Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories woman laying down and sheet over going into surgery
Health Lab
Older women more likely to receive heart surgery, die at low quality hospitals
Women over the age of 65 who require complex heart surgery are more likely than men to receive care at low quality hospitals — where they also die in greater numbers following the procedure, a Michigan Medicine study finds.
Woman Patient Preparing Surgery Anesthesia
Health Lab
Female heart patients less likely to have additional problems fixed during surgery
Two studies led by Michigan Medicine find that female patients who undergo heart surgery are less likely to have secondary ailments corrected during a procedure — despite guidelines that indicate they should.
light lights seen on dark navy screen
Health Lab
Researchers identify novel biomarker linked to renal cancer recurrence
Researchers from the University of Michigan Health Rogel Cancer Center have discovered a biomarker that could help identify which renal cancer patients have a higher risk of recurrence.
different cars from helicopter view on highways intersecting going all different ways seeing greenery and roads
Health Lab
Pediatric brain tumors rely on different metabolic “route” to fuel treatment resistance
Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.
cancer cell blue yellow
Health Lab
Accessibility issues in cancer care
Researchers at the University of Michigan are finding that many patients may be encountering significant barriers to cancer care, even from their first phone call to a clinic.
white blood cell with some blue on black background artistic looking
Health Lab
White blood cell “nets” could be early warning sign of major immunotherapy complication
When white blood cells, meant to protect the body from infection, are overly activated, they eject their DNA into nets, further disrupting the immune system and making patients more likely to develop a potentially severe reaction to immunotherapy.